Gene editing for neurodegenerative diseases-A review

Abstract

Gene editing is quickly gaining traction as a promising treatment option for a variety of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), Amyotrophic Lateral Sclerosis (ALS), and Frontotemporal Dementia (FD). Clinical investigations have so far failed to establish that there is any change in result other than the placebo effect. Efforts to discuss on some key areas: vectors and the identification of novel vector serotypes, the identification of new therapeutic targets, current techniques and some clinical uses of gene editing. To increase efficacy, these advancements are being evaluated separately and in combination. Certain advancements might pave the way for gene editing to be successful in treating these diseases.